Diagnostics, gastrointestinal and pelvic device company, Laborie Medical Technologies, has executed a definitive agreement to acquire Cogentix Medical Inc., developer of neurostimulation, endoscopy, and urology technology and devices. The deal was set at a cash purchase price of $3.85 per Cogentix share and enterprise value of $214 million. The share price is a 28 percent premium above the average closing price of Cogentix's common stock across the last 30 days. Under the deal, Laborie will acquire all outstanding shares of Cogentix for a total consideration of about $239 million. Read More
